Mr. Rieflin became Executive Chairman of NGM’s Board of Directors in September 2018, after having served as Chief Executive Officer of the company and a member of the Board over the prior eight years. Prior to joining NGM, he was President of XenoPort, Inc. (NASDAQ: XNPT), which was acquired by Arbor Pharmaceuticals in 2016, and Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik Inc. (NASDAQ: TLRK), which was acquired by Amgen Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE: ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. He currently serves on the Board of Directors of RAPT Therapeutics, Inc., Lyell Immunopharma, Inc. and Kallyope, Inc. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.

Dr. Woodhouse became Chief Executive Officer and a member of NGM’s board of directors in September 2018. He previously served as NGM’s Chief Financial Officer, joining the company in March 2015. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a Managing Director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. He currently serves on the Board of Directors of Surrozen Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.

Dr. Chen is NGM’s Founder and has served as a member of our board of directors and as Chief Scientific Officer since January 2008. He was also NGM’s President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Disorders, with responsibility for leading the company’s global research efforts in small molecule and biologic drug discovery for the treatment of human diseases affecting metabolism, bone, mineral balance and muscle. Prior to joining Amgen, he served as Vice President of Biology at Tularik where he guided drug discovery research in oncology, inflammation and metabolic disease. Dr. Chen’s pioneering work on a broad array of targets at both Amgen and Tularik not only opened up opportunities to study new aspects of biology and physiology across disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including Repatha^TM (evolocumab), a novel anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol.

Dr. Chen received a B.S. in Nutrition and Food Science from Fu-Jen Catholic University, and a M.S. in biochemistry from National Taiwan University. He completed his graduate training at the University of California, Berkeley in 1994, receiving a Ph.D. for his research on the mechanisms of transcription carried out in the laboratory of Prof. Robert Tjian.

Prior to his current role as NGM’s Chief Translational Officer, Dr. DePaoli served as NGM’s founding Chief Medical Officer (CMO).  Before joining NGM in 2010, Dr. DePaoli was CMO at IntreKin Therapeutics.  In this role he oversaw global development of INT131, a PPAR-gamma modulator, through a successful End of Phase 2 meeting with the FDA. He brings to NGM more than 20 years of experience as a clinician and translational researcher in diabetes, obesity and metabolic disease. Dr. DePaoli trained in Clinical and Molecular Endocrinology at the University of Chicago and in the Howard Hughes laboratory of Dr. Graham Bell. His clinical and translational research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute which led him to join Amgen in 1998 to champion the development of their cardiometabolic disease portfolio. His work at Amgen was pivotal in enabling multiple clinical applications of the adipocytokine leptin (Myalept). At Amgen, he also led a broad array of cardiometabolic, muscle and bone programs with a focus on translating novel pathways into the clinic. These pathways included: RANK Ligand (now Prolia and Xgeva), PCSK9 (Evolocumab), 11 Beta HSD-1, Myostatin, IL-1 receptor, Calcium Sensing Receptor (Sensipar), PPAR-gamma modulation, DPP-4 and MCH-R1. Dr. DePaoli also maintains a clinical endocrinology practice at the William Sansum Diabetes Center.

Dr. Learned joined NGM as Director of Research Operations in January 2008, providing strategic and operational support for our research efforts. Formerly a Director of Research in Metabolic Disorders at Amgen, he led in vivo pharmacology for several programs and played a significant operational role in the department. Previously, he was part of the Lead Discovery group at Tularik and was central to the identification and optimization of lead compounds for multiple projects in the diabetes and obesity programs, including several candidates selected for human clinical studies. Dr. Learned graduated from the University of California, Los Angeles with a B.S. in Biochemistry and received a Ph.D. in biochemistry from the University of California, Berkeley. He completed post-doctoral training at the Whitehead Institute for Biomedical Research, and subsequently served as an Assistant Professor in the Department of Biochemistry at the University of California, Davis.

Dr. Lieu joined NGM in March 2019 and brings more than 15 years of experience leading clinical development programs and executing integrated medical and commercial strategies across a spectrum of therapeutic areas.  In both large pharmaceutical and biotechnology companies, Dr. Lieu has led teams responsible for preclinical through phase 3 development, as well as medical affairs.  Prior to NGM, Dr. Lieu worked at Genentech as Vice President of Early Clinical Development for all non-oncology molecules. He also worked at Eli Lilly, where he held various leadership roles, including  Global Brand Development Leader for Taltz®, Managing Director and Vice President at Lilly’s internal early clinical development and research division Chorus , Head of Global Clinical Pharmacology for diabetes, and Senior Medical Director of U.S. Medical Affairs for a number of cardiovascular and autoimmune products. Prior to joining Lilly, Dr. Lieu was a co-founder and CEO of RetinoRx, LLC and Chief Medical Officer/Executive Vice President at Niles Therapeutics, Inc. Earlier in his career, he held clinical development leadership roles with Portola Pharmaceuticals, Inc. and CV Therapeutics, Inc. (acquired by Gilead).

Dr. Lieu was an attending cardiologist at San Francisco General Hospital from 2002-2013 and an adjunct Associate Clinical Medical Professor at University of California, San Francsico (UCSF). He completed his cardiology fellowship at UCSF, a postdoctoral research fellowship in molecular cardiology at the J. David Gladstone Research Institute at UCSF, and an internal medicine residency at Columbia Presbyterian Hospital. Dr. Lieu received his M.D. from Albert Einstein College of Medicine and B.A. from New York University.

Prior to joining NGM, Ms. Nolan Mangini served as President and Chief Financial Officer (CFO) of Castlight Health, a publicly traded San Francisco-based healthcare technology company. She joined Castlight in 2012 and assumed roles of increasing responsibility, ultimately being appointed CFO in 2016 followed by her additional appointment as President in 2019. At Castlight, Ms. Nolan Mangini was responsible for a wide range of functions including strategic and corporate planning, finance, investor relations, people, legal, real estate, customer support and business operations. Prior to joining Castlight, Ms. Nolan Mangini worked as a management consultant at Bain & Company, specializing in the health care and private equity practices. She began her career at the Henry J. Kaiser Family Foundation as a financial associate responsible for managing the allocation of the foundation’s endowment. Ms. Nolan Mangini currently serves on the Board of Directors of Artemis Health.

Ms. Nolan Mangini has a Master of Business Administration from the Graduate School of Business at Stanford University, a Master of Public Administration from the Kennedy School of Government at Harvard University and a Bachelor of Science in Economics from the Wharton School at the University of Pennsylvania.

Mr. Muma joined NGM in December 2019 and brings over 25 years of human resources leadership experience in the biopharmaceutical industry and in management consulting, most recently as Vice President, Human Resources for ORIC Pharmaceuticals. Prior to ORIC, Mr. Muma held the positions of Vice President, Human Resources for Roche China and Senior Director, Human Resources for Genentech. Mr. Muma also worked as executive compensation consultant to Fortune 500 companies at KPMG and Mercer in New York and San Francisco. Mr. Muma received a B.A. in Economics from the University of Michigan, and an M.B.A. from the University of Michigan Ross School of Business.

Prior to joining NGM as Senior Vice President, General Counsel and Chief Compliance Officer, Ms. Pierce served as Senior Vice President, Associate General Counsel at Jazz Pharmaceuticals since 2012. She brings to NGM over 25 years of experience providing legal guidance to public pharmaceutical and biotechnology companies.  Before Jazz, Ms. Pierce worked in various in-house positions, including Vice President and Senior Transactional Counsel at Amyris, Inc., Senior Vice President and General Counsel at Sunesis Pharmaceuticals, Inc., and earlier roles at the Institute for OneWorld Health, Tularik Inc. and ALZA Corporation.  Ms. Pierce received a B.A. in Latin Amercian Studies from Yale University and a J.D. from the Yale Law School.

Dr. Shen is a leading expert with more than 20 years of experience in the antibody and therapeutic protein field. He has a proven record of advancing pipelines from discovery to proof-of-concept in clinical stage to registration. Before joining NGM in 2013, Dr. Shen served as Vice President, Global Head of Biologics Development at TEVA Pharmaceuticals and managed the innovative biologics, biobetters and biosimilars portfolio across therapeutic areas. During his tenure, several biologics/biosimilars were successfully approved, including TBO-Filgrastim by FDA and Lipegfilgrastim by EMA. Prior to TEVA, Dr. Shen was Executive Director, Biologics Research and GlycoFi at Merck where he oversaw overall biologics pipeline from discovery to preclinical development. His professional career started at Amgen where he held positions of increasing responsibility, including site-head for the Protein Sciences Department in San Francisco, and was critical in advancing more than eight antibody drug candidates from research to clinical development and regulatory approval, including evolucumab (anti-PCSK9), romosozumab (anti-sclerostin) and denosumab (anti-RANKL). In addition, he has developed the mammalian full IgG display technology that is now widely used by the antibody field. Dr. Shen graduated from East China University of Science and Technology and received a Ph.D. from University of Toronto. He completed post-doctoral training at the Whitehead Institute for Biomedical Research.

Dr. Tian joined NGM in January 2008, providing leadership for our discovery research efforts. He was most recently the Scientific Director in the Metabolic Disorders Therapeutic Area at Amgen, responsible for early stage discovery research in the area of diabetes and lipid disorders. Prior to Amgen, he was responsible for the orphan G protein-coupled receptor drug discovery program at Tularik, successfully leading several projects in multiple therapeutic areas, including metabolic disease, inflammation and neurodegenerative disorders. During the course of these efforts, Dr. Tian and his team identified several clinical candidates for study in humans. Dr. Tian received a Ph.D. in Molecular and Cellular Biology at the University of Texas Southwestern Medical Center and completed post-doctoral training in Developmental Biology at Harvard University.